Literature DB >> 10910035

Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct.

E M Gordon1, P X Liu, Z H Chen, L Liu, M D Whitley, C Gee, S Groshen, D R Hinton, R W Beart, F L Hall.   

Abstract

Tumor invasion and associated angiogenesis evoke a remodeling of extracellular matrix components. Retroviral vectors bearing auxiliary matrix-targeting motifs (ie., collagen-binding polypeptides) accumulate at sites of newly exposed collagen, thus promoting tumor site-specific gene delivery. In this study, we assessed the antitumor effects of serial portal vein infusions of matrix-targeted vectors bearing a mutant cyclin G1 (dnG1) construct in a nude mouse model of liver metastasis. The size of tumor foci was dramatically reduced in dnG1 vector-treated mice compared with that in control vector- or PBS-treated animals (P = 0.0002). These findings represent a definitive advance in the development of targeted injectable vectors for metastatic cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10910035

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Epstein-Barr virus downregulates microRNA 203 through the oncoprotein latent membrane protein 1: a contribution to increased tumor incidence in epithelial cells.

Authors:  Haibo Yu; Jianhong Lu; Lielian Zuo; Qijia Yan; Zhengyuan Yu; Xiayu Li; Jin Huang; Lian Zhao; Hailin Tang; Zhaohui Luo; Qianjin Liao; Zhaoyang Zeng; Junyi Zhang; Guiyuan Li
Journal:  J Virol       Date:  2011-12-28       Impact factor: 5.103

2.  MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profiling in breast cancer cells.

Authors:  S Duygu Selcuklu; Mark T A Donoghue; Kristina Rehmet; Matheus de Souza Gomes; Antoine Fort; Prasad Kovvuru; Mohan K Muniyappa; Michael J Kerin; Anton J Enright; Charles Spillane
Journal:  J Biol Chem       Date:  2012-07-02       Impact factor: 5.157

3.  ELAS1-mediated inhibition of the cyclin G1-B'γ interaction promotes cancer cell apoptosis via stabilization and activation of p53.

Authors:  S Ohno; Y Naito; S Mukai; N Yabuta; H Nojima
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

Review 4.  Library screening and receptor-directed targeting of gammaretroviral vectors.

Authors:  Peter M Mazari; Monica J Roth
Journal:  Future Microbiol       Date:  2013-01       Impact factor: 3.165

5.  Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer.

Authors:  Evanthia Galanis; Stephanie K Carlson; Nathan R Foster; Val Lowe; Fernando Quevedo; Robert R McWilliams; Axel Grothey; Aminah Jatoi; Steven R Alberts; Joseph Rubin
Journal:  Mol Ther       Date:  2008-03-18       Impact factor: 11.454

Review 6.  Current advances in retroviral gene therapy.

Authors:  Youngsuk Yi; Moon Jong Noh; Kwan Hee Lee
Journal:  Curr Gene Ther       Date:  2011-06       Impact factor: 4.391

7.  Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.

Authors:  Sant P Chawla; Victoria S Chua; Lita Fernandez; Dorris Quon; William C Blackwelder; Erlinda M Gordon; Frederick L Hall
Journal:  Mol Ther       Date:  2009-10-13       Impact factor: 11.454

8.  Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with DeltaRex-G: A case report and literature review.

Authors:  Michael A Morse; Sant P Chawla; Terence Z Wong; Howard W Bruckner; Frederick L Hall; Erlinda M Gordon
Journal:  Mol Clin Oncol       Date:  2021-07-08

Review 9.  MicroRNA involvement in hepatocellular carcinoma.

Authors:  Laura Gramantieri; Francesca Fornari; Elisa Callegari; Silvia Sabbioni; Giovanni Lanza; Carlo M Croce; Luigi Bolondi; Massimo Negrini
Journal:  J Cell Mol Med       Date:  2008-12       Impact factor: 5.310

10.  Assessment of the evolution of cancer treatment therapies.

Authors:  Manuel Arruebo; Nuria Vilaboa; Berta Sáez-Gutierrez; Julio Lambea; Alejandro Tres; Mónica Valladares; Africa González-Fernández
Journal:  Cancers (Basel)       Date:  2011-08-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.